Verition Fund Management
CYTK icon

Verition Fund Management’s Cytokinetics CYTK Stock Holding History

Verition Fund Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,037
Closed -$1.37M – 3674
2025
Q1 		$1.37M Buy
34,037
+13,755
+68% +$632K 0.01% 1860
2024
Q4 		$954K Sell
20,282
-17,581
-46% -$913K ﹤0.01% 2083
2024
Q3 		$2M Buy
37,863
+27,098
+252% +$1.51M 0.01% 1418
2024
Q2 		$583K Sell
10,765
-151,554
-93% -$9.15M ﹤0.01% 1974
2024
Q1 		$11.4M Buy
+162,319
New +$12.6M 0.08% 290
2022
Q3 		– Sell
-6,970
Closed -$274K – 3076
2022
Q2 		$274K Buy
+6,970
New +$281K 0.01% 1766
2015
Q1 		– Sell
-15,988
Closed -$128K – 406
2014
Q4 		$128K Buy
+15,988
New +$68.6K 0.03% 274

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Verition Fund Management's CYTK Position: Q2 2025 in Review

Verition Fund Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 34,037 shares — an estimated $1.37M sold.

Verition Fund Management first reported a position in CYTK in Q4 2014 and held it in 7 quarters. The position peaked at $11.4M in Q1 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Verition Fund Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 34,037 Cytokinetics shares in Q2 2025, an estimated $1.37M.
  • Verition Fund Management first reported a position in Cytokinetics in Q4 2014 and held it in 7 quarters.
  • Verition Fund Management's Cytokinetics position peaked at $11.4M in Q1 2024.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.